Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies

ABSTRACT: We have developed a novel mTOR pathway inhibitor via targeting SIN1. We used multiple proteomics analyses to determine mechanism of action of our novel Sin1 inhibitor and compare to other mTOR pathway inhibitors.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Leukemia Cell

DISEASE(S): Leukemia

SUBMITTER: Michael Caldwell

LAB HEAD: Leonidas Platanias

PROVIDER: PXD040952 | Pride | 2026-01-26

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20210820_vcs075_21-2659_Platanias_Beauchamp_01-Control-1_H1.raw	Raw
	20210820_vcs075_21-2659_Platanias_Beauchamp_01-Control-1_H2.raw	Raw
	20210820_vcs075_21-2659_Platanias_Beauchamp_01-Control-1_H3.raw	Raw
	20210820_vcs075_21-2659_Platanias_Beauchamp_01-Control-1_H4.raw	Raw
	20210820_vcs075_21-2659_Platanias_Beauchamp_02-rapamycin-1_H1.raw	Raw

Items per page:

1 - 5 of 35

Similar Datasets

A cell competition-based drug screen identifies a novel compound that induces dual c-Myc degradation and p53 activation

Project description:BCR-Abl is a driver oncogene that causes chronic myeloid leukemia and a subset of acute lymphoid leukemias. Although tyrosine kinase inhibitors provide an effective treatment for these diseases, they generally do not kill leukemic stem cells. Leukemic stem cells are cancer-initiating cells that compete with normal hematopoietic stem cells for the bone marrow niche. Using BCR-Abl as a model oncogene, we performed a drug screen based on competition between isogenic untransformed cells and BCR-Abl-transformed cells, and identified several compounds that selectively target BCR-Abl-transformed cells. Systems-level analysis of one of these novel compounds, DJ34, revealed that it induced depletion of c-Myc and activation of p53. c-Myc depletion occurred in a wide range of tumor types, including leukemia, lymphoma, lung, glioblastoma and breast cancer. Further analyses revealed that DJ34 interferes with c-Myc synthesis at the level of transcription, and we provide data showing that DJ34 is a DNA intercalator and topoisomerase II inhibitor. Physiologically, DJ34 induced apoptosis, cell cycle arrest and cell differentiation, and primary leukemic stem cells were particularly sensitive to DJ34. Taken together, we have identified a novel compound that dually targets c-Myc and p53 in a wide variety of cancers, and with particularly strong activity against leukemic stem cells.

2020-12-07 | PXD018812 | Pride

Changes in global gene expression in SIN1 knock-out murine epithelial fibroblasts

Project description:RNA from wt and SIN1 knock-out MEF cell lines were compared Using affymetrix murine gene chip, the effects of SIN1 ablation on global gene transcription were assessed

2016-08-25 | GSE65464 | GEO

Sin1-mTORC2 Augments Lipid Anabolism of Tumor-associated Macrophages to Limit the Type I Interferon-dependent Anti-tumor Immunity

Project description:The biological consequences and mechanisms of metabolic reprogramming of macrophages in the tumor microenvironment (TME) remain largely elusive. Here we showed, in part by myeloid-specific ablation of Sin1, a key component of mammalian target of rapamycin complex (mTORC) 2, that the Sin1-mTORC2-Akt-sterol regulatory element-binding proteins (SREBPs) signaling was augmented in tumor-associated macrophages (TAMs), leading to excessive lipid synthesis and accumulation, which consequently impaired the STING-dependent type I interferon production and CD8+ T cell mediated anti-tumor immunity. The ability of Sin1 deficiency in TAMs to inhibit lipid synthesis and enhance anti-tumor immunity could be blunted by the accumulation of cholesterol/lipids in TAMs. Furthermore, genetic ablation of Sin1 in TAMs or pharmacologic inhibition of lipid anabolism acted synergistically with immune checkpoint blockade (ICB)-based cancer therapy to control tumor growth. Finally, elevated Sin1-mTORC2-Akt activity and lipid anabolism as well as decreased type I IFN responses were all observed in TAMs from human colon cancers and tightly associated with poor patient survival. Together, our study uncovers a novel role of Sin1-regulated lipid anabolic pathway in TAMs which acts as a metabolic checkpoint for anti-tumor immunity via limiting a STING-dependent type I IFN response.

2025-03-17 | GSE198880 | GEO

Changes in global gene expression in SIN1 knock-out murine epithelial fibroblasts

Project description:RNA from wt and SIN1 knock-out MEF cell lines were compared Using affymetrix murine gene chip, the effects of SIN1 ablation on global gene transcription were assessed RNA from wild type and SIN1 knock out cells was purified and differences in gene expression between the two sets. MEFs were derived from C57BL/6 (Jacinto et. al. Cell. 2006 Oct 6;127(1):125-37. Epub 2006 Sep 7

2016-08-25 | E-GEOD-65464 | biostudies-arrayexpress

Phosphoproteomic analysis of Aurora Kinase B inhibition in WT and Cdh1 mutant RPE1 cells

Project description:RPE1 cells that were either WT or Cdh1 mutant were treated with and without the AurKB inhibitor Barasertib, and assessed by phosphoproteomic analysis

2023-10-12 | PXD044042 | Pride

Proteome Landscape of Early Stage Hepatocellular Carcinoma Identifies Proteomic Subtypes and New Therapeutic Targets - Phosphorylation data

Project description:Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers, the second leading cause of cancer mortality worldwide. Although HCC surgical treatment may be curative in the early stages, its five-year overall survival is only 50-70%. Advances in proteomic technologies have expanded the breadth and depth of cancer proteome characterization. Here, we present the largest characterization effort on proteomic profiling of 222 tumor and paired non-tumor tissues in clinically early HCC (Barcelona Clinic Liver Cancer (BCLC) stage 0 and A). Quantitative proteomic data identified three more-refined subtypes in the early- stage cohort of HCC (termed S-I, S-II and S-III) with different clinical outcomes. S-I retained hepatic detoxification and metabolic functions with the best prognosis, S-II increased molecular expression related to proliferation, and S-III showed distinct enrichment of tumor metastasis and immune response pathways and the poorest prognosis. The subtype specific signatures targeted by known FDA approved drugs or inhibitors under clinical investigations for HCC provide a novel resource for HCC therapeutic targets. A new mechanism of disrupted cholesterol homeostasis with aberrant accumulation of cholesteryl esters was also highlighted in S-III. Thus, this study represents the first proteomic stratification of early-stage HCC, providing insights into tumor biology and personalized targeted therapy.

2019-03-01 | PXD008373 | Pride

Investigating the effect of Aurora Kinase B inhibition in WT and CDH1 mutant primary neuron cultures

Project description:Primary cultures of mouse cerebellar granule neurons at DIV2 that were either WT or Cdh1 mutant were treated with and without the Aurora B inhibitor Barasertib and assessed by phosphoproteomic analysis

2023-10-12 | PXD045116 | Pride

Phosphoproteomic analysis of mouse neurons with SRPK2 overexpression or knockdown

Project description:SRPK2 was identified as a presynaptic protein kinase involved in the regulation of neurotransmitter release. The phosphoproteome of mouse primary neurons was screened, under the conditions of SRPK2 overexpression and SRPK2 knockdown, to identify candidate substrates of SRPK2.

2022-02-14 | PXD016636 | Pride

Development of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies

Project description:We have developed a novel mTOR pathway inhibitor via targeting SIN1. We used multiple proteomics analyses to determine mechanism of action of our novel Sin1 inhibitor and compare to other mTOR pathway inhibitors.

2026-01-26 | PXD040950 | Pride

Development of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies

2026-01-26 | PXD040955 | Pride